A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Huang, Zhifeng ^a,b   Wang, Huiyan ^b   Lu, Meifei ^a   Sun, Chuanchuan ^a   Wu, Xiaoping ^c   Tan, Yi ^a,d   Ye, Chaohui ^a   Zhu, Guanghui ^a   Wang, Xiaojie ^a   Cai, Lu ^a,d   Li, Xiaokun ^a,b,c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Basic Medical College   (China)

^c JINAN UNIVERSITY   (China)

^d University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRALDEHYDE; GLUCOSE; MACROGOL; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 21; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ALDEHYDE; ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANION EXCHANGE CHROMATOGRAPHY; ANTIDIABETIC EFFECT; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEGYLATION; PROADIPOCYTE; PROTEIN SECONDARY STRUCTURE; RAT; TEMPERATURE SENSITIVITY; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; CELL STRAIN 3T3; CHEMISTRY; HUMAN; LIPID METABOLISM; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALIA; RATTUS;

3T3-L1 CELLS; ALDEHYDES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG STABILITY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; MALE; MICE; POLYETHYLENE GLYCOLS; RATS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79958126904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020669     Document Type: Article

References (40)

1. Baird A, Klagsbrun M, (1991) The fibroblast growth factor family. Cancer Cells 3: 239-243.
2. McKeehan WL, Wang F, Kan M, (1998) The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol 59: 135-176.
3. Beenken A, Mohammadi M, (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253.
4. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603.
5. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635.
6. Razzaque MS, Lanske B, (2007) The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 194: 1-10.
7. Nishimura T, Nakatake Y, Konishi M, Itoh N, (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206.
8. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, et al. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57: 1246-1253.
9. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Koster A, et al. (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55: 2470-2478.
10. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, et al. (2008) FGF21 is an Akt-regulated myokine. FEBS Lett 582: 3805-3810.
11. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, et al. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774-781.
12. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250-259.
13. Wang H, Xiao Y, Fu L, Zhao H, Zhang Y, et al. (2010) High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol 10: 14.
14. Katre NV, Knauf MJ, Laird WJ, (1987) Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci U S A 84: 1487-1491.
15. Kitamura K, Takahashi T, Takashina K, Yamaguchi T, Noguchi A, et al. (1990) Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem Biophys Res Commun 171: 1387-1394.
16. Lee BK, Kwon JS, Kim HJ, Yamamoto S, Lee EK, (2007) Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity. Bioconjug Chem 18: 1728-1734.
17. Xiao J, Burn A, Tolbert TJ, (2008) Increasing solubility of proteins and peptides by site-specific modification with betaine. Bioconjug Chem 19: 1113-1118.
18. Marsac Y, Cramer J, Olschewski D, Alexandrov K, Becker CF, (2006) Site-specific attachment of polyethylene glycol-like oligomers to proteins and peptides. Bioconjug Chem 17: 1492-1498.
19. Veronese FM, Mero A, Caboi F, Sergi M, Marongiu C, et al. (2007) Site-specific pegylation of G-CSF by reversible denaturation. Bioconjug Chem 18: 1824-1830.
20. Wu X, Li Y, (2009) Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis. Aging (Albany NY) 1: 1023-1027.
21. Fukumoto S, (2008) Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23. Intern Med 47: 337-343.
22. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, et al. (2007) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27: 3417-3428.
23. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, et al. (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282: 26687-26695.
24. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, et al. (2007) BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 104: 7432-7437.
25. Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, et al. (2008) FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 215: 1-7.
26. Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, et al. (2008) betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 22: 1006-1014.
27. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, et al. (2009) Different roles of N- and C- termini in the functional activity of FGF21. J Cell Physiol 219: 227-234.
28. Yie J, Hecht R, Patel J, Stevens J, Wang W, et al. (2009) FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 583: 19-24.
29. Kang CE, Tator CH, Shoichet MS, (2010) Poly(ethylene glycol) modification enhances penetration of fibroblast growth factor 2 to injured spinal cord tissue from an intrathecal delivery system. J Control Release 144: 25-31.
30. Kurfurst MM, (1992) Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 200: 244-248.
31. Pasut G, Veronese FM, (2009) PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 61: 1177-1188.
32. Veronese FM, Mero A, (2008) The impact of PEGylation on biological therapies. BioDrugs 22: 315-329.
33. Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C, (2002) Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 54: 477-485.
34. Scott MD, Chen AM, (2004) Beyond the red cell: pegylation of other blood cells and tissues. Transfus Clin Biol 11: 40-46.
35. Kuan CT, Wang QC, Pastan I, (1994) Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J Biol Chem 269: 7610-7616.
36. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149: 6018-6027.
37. Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, et al. (2009) Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin resistant mouse models----Association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 297: E1105-E1114.
38. Uonaga T, Toyoda K, Okitsu T, Zhuang X, Yamane S, et al. (2010) FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model. Islets 2: 247-251.
39. Niall HD, (1973) Automated Edman degradation: the protein sequenator. Methods Enzymol 27: 942-1010.
40. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.